Targeted Disease(s):
COPD
Purpose of Study:
Tozorakimab is hypothesized to have a beneficial effect in patients with COPD by reducing the frequency and severity of COPD exacerbations and improving COPD symptoms and quality of life.
Study Dates:
October 1, 2024 - July 30, 2025
Study Location:
UT
Funding Source:
AstraZeneca
Contact:
Pantheon Clinical Research
385-281-0550
mgibb@pantheonclinical.com
ClinicalTrails.gov Identifier:
NCT06040086
